Research programme: metabolic disorder therapeutics - Relburn MetabolomicsAlternative Names: RLBN 1001; RLBN 2020 series; RLBN 3010 series
Latest Information Update: 13 Jun 2014
At a glance
- Originator Relburn Metabolomics
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gout
Most Recent Events
- 03 Jun 2014 Preclinical trials in Gout in USA (unspecified route)